The overwhelming demands on health care resources in treating patients with COVID-19 and the heterogeneity in illness presentation highlights the need for strategies to predict which individuals are at risk for greater symptom severity.
Researchers are exploring affective lability as a therapeutic target for bipolar disorder, but limited evidence exists on its prevalence and impact among people with schizophrenia and other psychosis spectrum disorders.
Researchers examined the prevalence of co-occurring psychiatric and medical conditions of pregnant individuals hospitalized with and without cannabis use disorder by concomitant substance use disorders.
Researchers examined nationwide data from the Welsh Demographic Service Dataset to determine if absence and exclusion from school were associated with a record of neurodevelopmental disorder, mental disorder, and self-harm.
Authors analyzed the documentation of primary care professionals from electronic health records (EHRs) to find out the rate of PTBM recommendation for 4-5 year old patients with an ADHD diagnosis, ADHD symptoms or who were prescribed ADHD medication.
Researchers in the United Kingdom analyzed genetic and phenotype data from the UK Biobank of 385,793 individuals aged 37 to 73 years.
In a randomized placebo-controlled clinical trial, researchers measured whether methylphenidate, a catecholaminergic compound, compared with placebo decreases the severity of apathy in individuals with Alzheimer disease.
Investigators assessed the effect of micronutrients in the form of vitamin and mineral supplementation in pediatric patients with attention-deficient/hyperactivity disorder.
A researcher from Austin Regional Clinic in Texas retrospectively assessed treatment outcomes among pediatric patients with ADHD.
Researchers conducted Permanent Product Measure of Performance assessments at screening or baseline in adults aged 18 to 60 years with ADHD.
